×
For best experience we recommend to activate Javascript in your browser.
CEBPG antibody (AA 1-150)
This Rabbit Polyclonal antibody specifically detects CEBPG in WB, IHC, IP and ICC. It exhibits reactivity toward Mouse.
Quick Overview for CEBPG antibody (AA 1-150) (ABIN7613797)
Target
See all CEBPG Antibodies
CEBPG
(CCAAT/enhancer Binding Protein (C/EBP), gamma (CEBPG))
Reactivity
All reactivities for CEBPG antibodies
Mouse
Host
All hosts for CEBPG antibodies
Rabbit
Clonality
All clonalities for CEBPG antibodies
Polyclonal
Conjugate
All conjugates for CEBPG antibodies
This CEBPG antibody is un-conjugated
Application
All applications for CEBPG antibodies
Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
Product Details anti-CEBPG Antibody
(hide)
Binding Specificity
All epitopes for CEBPG antibodies
AA 1-150
Purpose
CCAAT/Enhancer Binding Protein Gamma (CEBPg) Polyclonal Antibody
Sequence
Met1~Gln150
Characteristics
The CCAAT/Enhancer Binding Protein Gamma (CEBPg) Polyclonal Antibody (Species: Mouse) has been validated for the following applications: WB, IHC, ICC, IP.
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
0.5 mg/mL
Buffer
PBS, pH 7.4, containing 0.02 % Sodium azide, 50 % glycerol
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.
Expiry Date
12 months
Target Details for CEBPG
(hide)
Target
CEBPG
(CCAAT/enhancer Binding Protein (C/EBP), gamma (CEBPG))
Alternative Name
CEBPg
Gene ID
12611
UniProt
P53568
Pathways
Positive Regulation of Response to DNA Damage Stimulus
Recently viewed
(hide)
Chat with us , powered by LiveChat